Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344736 | 0.94 | ALDH1A1 (0.31) | ALDH1A1TDP1TSHRGAA | |
| SCHEMBL10840351 | 0.81 | HMGCR (0.44) | ALDH1A1TDP1TSHR | |
| SCHEMBL22995721 | 0.79 | ALDH1A1 (0.30) | ALDH1A1TDP1 | |
| Acetic Acid SCHEMBL22472063 | 0.79 | CA1 (0.32) | ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL22757208 | 0.77 | ALDH1A1 (0.32) | ALDH1A1TDP1TSHR | |
| SCHEMBL11735750 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHR | |
| SCHEMBL9129137 | 0.74 | ALDH1A1 (0.35) | ALDH1A1TDP1TSHRGAASMN1; SMN2 | |
| SCHEMBL11413382 | 0.73 | — | — | |
| SCHEMBL557272 | 0.72 | — | — | |
| SCHEMBL13554077 | 0.72 | TSHR (0.39) | TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895586-B2 | Methods of treating emesis | HELSINN HEALTHCARE SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20130231315-A1 | MODIFIED 4-PHENYL-PYRIDINE DERIVATIVES | HELSINN HEALTHCARE SA (CH) | 2013-09-05 | — | — | US | disclosed |
| US-6218427-B1 | AS ENDOTHELIN RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0924207-A1 | CHROMENE-3-CARBOXYLATE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0134529-B1 | 7-ALPHA-SUBSTITUTED 3-OXO-17-ALPHA-PREGN-4-ENE 21-17 CARBOLACTONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-03-21 | — | — | EP | disclosed |
| EP-0071153-B1 | ANDROSTANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-09-10 | — | — | EP | disclosed |
| EP-0134529-A2 | 7-Alpha-substituted 3-oxo-17-alpha-pregn-4-ene 21-17 carbolactones, process for their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-03-20 | — | — | EP | disclosed |
| EP-0051143-B1 | PROCESS FOR THE PREPARATION OF 3-BETA, 7-BETA-DIHYDROXY-DELTA-5 STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-07-04 | — | — | EP | disclosed |
| EP-0043994-B1 | 5-BETA-HYDROXY-DELTA-6-STEROIDS AND PROCESS FOR THEIR PREPARATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-06-06 | — | — | EP | disclosed |
| EP-0071153-A1 | Androstane derivatives, process for their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-02-09 | — | — | EP | disclosed |
| EP-0051143-A1 | Process for the preparation of 3-beta, 7-beta-dihydroxy-delta-5 steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-05-12 | — | — | EP | disclosed |
| WO-1982000294-A1 | 5BETA-HYDROXY-DELTA 6-STEROID DERIVATIVES AND METHOD FOR THEIR PREPARATION | WIECHERT R | 1982-02-04 | — | — | WO | disclosed |
| EP-0043994-A1 | 5-Beta-hydroxy-delta-6-steroids and process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-01-20 | — | — | EP | disclosed |
| US-4111955-A | PESTICIDES | UNION CARBIDE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231315-A1 | MODIFIED 4-PHENYL-PYRIDINE DERIVATIVES | BDKRB2, BDKRB1, TACR1 | ALDH1A1 1281/4885TDP1 3776/4885TSHR 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.